AP NEWS

QIAGEN Applauds Bold UN Plan for Tuberculosis Prevention and Care

September 28, 2018

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Sep 28, 2018--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today applauded a commitment by world leaders attending the first-ever high-level United Nations meeting on tuberculosis (TB) to mobilize $13 billion a year by 2022 to implement prevention and care for TB, the world’s most deadly infectious disease. The heads of state meeting at the United Nations General Assembly pledged to ensure that 40 million people who are diagnosed with tuberculosis receive the care they need by the end of 2022 and agreed to provide preventive testing and treatment to 30 million people.

Prevention is essential to successful TB control because tuberculosis often infects the body, then remains inactive and undetected until – if untreated – it can surface as the active, contagious disease threatening the lungs and sometimes other organs. An estimated one-third of the world’s population has latent tuberculosis infection, and up to 10 percent of infected persons will progress to active TB if untreated. Screening of at-risk population groups and treatment for those infected can prevent latent TB from progressing to active disease. QIAGEN’s QuantiFERON-TB Gold Plus (QFT-Plus), the most accurate test available for latent TB infection, is now being implemented worldwide in tuberculosis control programs.

“We are pleased to see this bold commitment by world leaders to step up the urgent fight against tuberculosis – and the unprecedented recognition and funding for TB prevention. This demonstration of political will is critical if we are to eradicate the world’s deadliest infectious disease,” said Dr. Masae Kawamura, M.D., Senior Director, TB Medical and Scientific Affairs, at QIAGEN, who attended the UN meeting on tuberculosis. “QIAGEN continues to be a committed partner with the World Health Organization, public health agencies and private organizations around the world to provide the most accurate, cost-effective screening available for latent TB. As this new commitment takes hold, we expect screening with QuantiFERON-TB Gold Plus to play a major role in preventing disease and saving lives.”

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005138/en/

CONTACT: QIAGEN

Investor Relations

John Gilardi

+49 2103 29 11711

or

Dr. Sarah Fakih

+49 2103 29 11457

e-mail:ir@QIAGEN.com

or

Public Relations

Dr. Thomas Theuringer

+49 2103 29 11826

or

Robert Reitze

+49 2103 29 11676

e-mail:pr@QIAGEN.com

KEYWORD: AUSTRIA UNITED STATES EUROPE NORTH AMERICA MARYLAND GERMANY SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PUBLIC POLICY/GOVERNMENT PHARMACEUTICAL OTHER GOVERNMENT

SOURCE: QIAGEN

Copyright Business Wire 2018.

PUB: 09/28/2018 06:00 AM/DISC: 09/28/2018 06:01 AM

http://www.businesswire.com/news/home/20180928005138/en

AP RADIO
Update hourly